舒利迭联合孟鲁司特钠治疗支气管哮喘的代谢组学研究

Metabolomics study of sulidate combined with montelukast sodium in the treatment of bronchial asthma

关键词:  代谢组学  舒利迭  孟鲁司特钠  支气管哮喘  血浆代谢成分

Key words:  metabolomics  sulidate  montelukast  bronchial asthma  plasma metabolic component

摘要:

目的 基于代谢组学探讨舒利迭联合孟鲁司特钠对支气管哮喘作用的机制。方法 以2016年5月—2018年12月收治的140例支气管哮喘患者为对象，均行舒利迭联合孟鲁司特钠治疗，并采用LC-MS/MS进行代谢组学检测，考察联合用药的治疗效果。结果 治疗后患者的潜在性代谢标志物锌、多巴胺、半胱氨酸、胆碱、乙酰乙酸、同型半胱氨酸、腺嘌呤、组胺以及鸟氨酸等与治疗前有显著差异，锌、多巴胺和半胱氨酸表现出上升趋势，其他物质则表现出降低趋势。结论 舒利迭联合孟鲁司特钠不仅能调节支气管哮喘患者的氨基酸代谢，促使其免疫功能增强，而且还能提升患者抗凋亡能力以及抗氧化能力，通过改善氨转运，对神经递质与细胞信号进行调控，同时对激素水平以及能量代谢进行调节。

Abstract:

OBJECTIVE To explore the mechanism of the effects of sulidate combined with montelukast sodium on bronchial asthma based on metabolomics.METHODS A total of 140 elderly patients with bronchial asthma from May 2016 to December 2018 were treated with sulidate combined with montelukast sodium, and LC-MS/MS-based on metabolic analysis was performed to assess the therapeutic benefits of the combination medication.RESULTS Potential metabolic markers of elderly patients after treatment were zinc, dopamine, cysteine, choline, acetoacetate, homocysteine, adenine, histamine, and ornithine, and the first three substances had an upward trend, while other substances showed a downward trend. After treatment, the plasma metabolism of patients was significantly different from that before treatment.CONCLUSION sulidate combined with montelukast sodium can not only regulate the amino acid metabolism of patients with bronchial asthma, and enhance their immune function, but also improve their anti-apoptosis and anti-oxidation capabilities. It can regulate the level of neurotransmitters by inhancing ammonia transport, regulate cellular signaling, hormone levels and energy metabolism.